ANNEX I, Regulation (EU) 2024/1701

In forcesince 11 Mar 2024

Annexes I, II, and III to Regulation (EC) No 1234/2008 are amended as follows:

(1)

Annex I is amended as follows:

(a)

in point 1, point (c) is replaced by the following:

‘(c) replacement of a biological active substance with one of a slightly different molecular structure where the efficacy or safety characteristics are not significantly different, with the exception of the following:

changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza;

replacement or, upon agreement of the relevant authorities, addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine;

replacement or, upon agreement of the relevant authorities, addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences, for a human vaccine other than for human influenza or coronavirus that has the potential to address a public health emergency in the Union;’;

(b)

in point 2, point (e) is replaced by the following:

‘(e) change or addition of a new route of administration.

[For parenteral administration, it is necessary to distinguish between intra-arterial, intravenous, intramuscular, subcutaneous and other routes.’;]

(c)

point 3 is deleted;

(2)

Annex II is amended as follows:

(a)

point 1 is amended as follows:

(i)

point (f) is replaced by the following:

‘(f) variations related to the tightening of specification limits, where the change is not a consequence of any commitment from previous assessment to review specification limits and does not result from unexpected events arising during manufacture;’;

(ii)

the following point (g) is added:

‘(g) variations related to changes to a medical device that is an integral part of or in exclusive use with the medicinal product which have no impact on the quality, safety or efficacy of the medicinal product.’;

(b)

point 2 is amended as follows:

(i)

point (e) is deleted;

(ii)

point (f) is replaced by the following:

‘(f) variations related to the introduction of a new design space, where the design space has been developed in accordance with the relevant European and international scientific guidelines;’;

(iii)

the following point (fa) is inserted after point (f):

‘(fa) variations related to the introduction of a post approval change management protocol where the protocol has been developed in accordance with the relevant European and international scientific guidelines;’;

(iv)

points (g), (h), (i) and (k) are deleted;

(v)

point (l) is replaced by the following:

‘(l) variations related to the replacement or, upon agreement of the relevant authorities, addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine;’;

(vi)

the following points (m) and (n) are added:

‘(m) variations related to the replacement or, upon agreement of the relevant authorities, addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences of a human vaccine that has the potential to address a public health emergency;

(n)

variations related to changes to a medical device that is an integral part of or in exclusive use with the medicinal product which may have a significant impact on the quality, safety or efficacy of the medicinal product.’;

(3)

Annex III is amended as follows:

(a)

points 6, 7 and 8 are replaced by the following:

‘6. All variations in the group relate to a project intended to improve the manufacturing process and the quality of the medicinal product concerned or its active substances, including related administrative changes.

7.

All variations in the group are changes affecting the quality of a human pandemic influenza or coronavirus vaccine.

8.

All variations in the group are changes to the pharmacovigilance system referred to in Article 8(3), point (ia) of Directive 2001/83/EC.’;

(b)

point 13 is deleted;

(c)

point 14 is replaced by the following:

‘14. All variations in the group are consequential to a specific procedure or condition carried out pursuant to Article 14(8) of Regulation (EC) No 726/2004 or Article 22 of Directive 2001/83/EC.’.